Zhongnan Hospital of Wuhan University
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China34 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) | Adnexal Diseases, Carcinoma, Ovarian Epithelial, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, breast cancer, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cervix disorder, endocrine system disorder, endometrial carcinoma, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, gonadal disorder, head and neck squamous cell carcinoma, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, respiratory system disorder, respiratory tract neoplasm, skin disorder, small cell lung carcinoma, squamous cell carcinoma, transitional cell carcinoma, urothelial carcinoma, uterine disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT04152499 | |
| Active Surveillance and Safety/Efficacy Evaluation of Innovative Devices for Structural Heart Disease Intervention | Biodegradable Patent Foramen Ovale Closure Device; Transcatheter Mitral Valve Edge-to-Edge Repair System | Recruiting | Not stated | 2026-09-29 | NCT07848152 | |
| A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors | Advanced Cancer | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-29 | NCT04495296 | |
| Catheter-Oriented Unloading and Recovery With a Left Ventricular Assist Gear: Efficacy in Post Cardiotomy Cardiogenic Shock | Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Shock, Cardiogenic, cardiovascular disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, vascular disorder | Recruiting | Not applicable | 2026-09-02 | NCT07560085 | |
| Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis | Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, immune system disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis | Recruiting | Phase 2 | 2026-09-01 | NCT07796516 | |
| A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Not yet recruiting | Phase 3 | 2026-08-31 | NCT07795346 | |
| A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 1 | 2026-08-27 | NCT05461768 | |
| PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2026-07-29 | NCT06419621 | |
| SMP-656 for HER2-Positive Advanced Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Not yet recruiting | Phase 2 | 2026-07-24 | NCT07726342 | |
| A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy. | Pulmonary Arterial Hypertension PAH | Recruiting | Phase 1 / Phase 2 | 2026-07-22 | NCT07593027 | |
| Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, thrombocytosis disease | Active, not recruiting | Phase 3 | 2026-07-22 | NCT04285086 | |
| The Value of Bowel Sounds in Evaluating Postoperative Intestinal Function Recovery in Colorectal Cancer Patients | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, intestinal obstruction, neoplasm, rectal disorder | Recruiting | Not stated | 2026-07-15 | NCT07705139 | |
| PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke | Arterial Occlusive Diseases, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Atherosclerotic, arteriosclerosis disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, intracranial arterial disease, intracranial arteriosclerosis, nervous system disorder, vascular disorder | Not yet recruiting | Phase 4 | 2026-07-15 | NCT07466251 | |
| RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-07-14 | NCT07416474 | |
| A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitis | Recruiting | Phase 3 | 2026-07-08 | NCT07282353 | |
| PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis | Arterial Occlusive Diseases, Intracranial Atherosclerosis, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Atherosclerotic, arteriosclerosis disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, intracranial arterial disease, intracranial arteriosclerosis, nervous system disorder, vascular disorder | Recruiting | Phase 4 | 2026-06-12 | NCT06902740 | |
| Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere | Unresectable Hepatocellular Carcinoma | Active, not recruiting | Phase 3 | 2026-06-09 | NCT06900543 | |
| Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure | Finerenone; HFpEF - Heart Failure With Preserved Ejection Fraction; TAVI(Transcatheter Aortic Valve Implantation) | Not yet recruiting | Phase 3 | 2026-05-08 | NCT07575672 | |
| A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Active, not recruiting | Phase 1 | 2026-05-01 | NCT03913949 | |
| Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-03-27 | NCT07498478 | |
| A Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cell Injection for the Treatment of Severe Acute Respiratory Distress Syndrome | Respiration Disorders, adult acute respiratory distress syndrome, lung disorder, respiratory system disorder | Recruiting | Phase 1 / Phase 2 | 2026-02-17 | NCT07413978 | |
| Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations | Cirrhosis, Familial, with Pulmonary Hypertension, Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Not yet recruiting | Phase 3 | 2026-01-09 | NCT07328919 | |
| The Efficacy and Safety of Intracranial Stent (Tonbridge) in Endovascular Treatment of Symptomatic Intracranial Atherosclerotic Stenosis | Arterial Occlusive Diseases, Intracranial Atherosclerosis, arteriosclerosis disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, intracranial arterial disease, intracranial arteriosclerosis, nervous system disorder, vascular disorder | Recruiting | Not applicable | 2026-01-02 | NCT05757505 | |
| A Clinical Study of YL205 in Patients With Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2025-12-23 | NCT06459973 | |
| A Study of Telitacicept for IgA Nephropathy (TELIGAN) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Active, not recruiting | Phase 3 | 2025-12-16 | NCT05799287 |